ArticleBMC infectious diseases2026
Incidence of Voriconazole-induced periostitis in a tertiary medical center: a single-center retrospective analysis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveVoriconazole is a commonly used antifungal medication, particularly for treating invasive pulmonary aspergillosis and as prophylaxis in hematologic malignancies. However, it can cause adverse effects, including periostitis—a painful inflammation of the periosteum. Reported incidence rates of voriconazole-induced periostitis vary widely. This study aimed to determine the incidence and characteristics of voriconazole-induced periostitis in a large cohort of patients with hematologic malignancies at a tertiary medical center, using various imaging modalities.
methodsA retrospective cohort study was conducted at Rambam Health Care Campus, including patients treated with voriconazole for at least 90 days between September 2015 and December 2022. Patients diagnosed with invasive pulmonary aspergillosis were evaluated. Imaging studies performed post-treatment initiation were reviewed for periostitis, confirmed by senior radiologists.
resultsAmong 157 patients treated for invasive pulmonary aspergillosis, 110 met the inclusion criteria. Four patients (3.6%, 95% CI 1.0% − 8.8%) demonstrated radiological signs of periostitis, most commonly detected via chest CT. Humeral involvement was present in all cases, and rib involvement occurred in 75%. Follow-up imaging did not show resolution due to ongoing treatment, patient mortality, or lack of follow-up.
conclusionThe incidence of voriconazole-induced periostitis in this cohort was lower than previously reported. Although rare, periostitis can significantly impact patient comfort and treatment decisions. CLINICAL TRIAL: Not applicable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.